Sensitive methods for evaluation of antibodies for host cell protein analysis and screening of impurities in a vaccine process

Vaccine

Volumn 32, Issue 24, 2014, Pages 2911-2915

  Lundström, Christine Sund ^a   Mattsson, Anna ^a   Lövgren, Karin ^b   Eriksson, Åsa ^a   Sundberg, Åsa Liljegren ^a   Lundgren, Mats ^a   Nilsson, Camilla Estmer ^a  

^a GE Healthcare Bio Sciences AB   (Sweden)

^b Isconova AB   (Sweden)

Author keywords

2 D DIGE; Adjuvant; Biacore; Host cell protein; Influenza virus; SPR

Indexed keywords

CELL PROTEIN; HOST CELL PROTEIN; INFLUENZA VACCINE; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DRUG IMPURITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HOST CELL; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PURIFICATION; SURFACE PLASMON RESONANCE; VACCINE PRODUCTION; VERO CELL LINE; VIRUS PURIFICATION; WESTERN BLOTTING;

2-D DIGE; ADJUVANT; BIACORE; HOST CELL PROTEIN; INFLUENZA VIRUS; SPR;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; ANTIBODY AFFINITY; BLOTTING, WESTERN; CERCOPITHECUS AETHIOPS; PROTEINS; SURFACE PLASMON RESONANCE; TECHNOLOGY, PHARMACEUTICAL; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; VACCINES; VERO CELLS;

EID: 84899934636     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.02.032     Document Type: Article

References (13)

1. Cantin R., Methot S., Tremblay M.J. Plunder and stowaways: incorporation of cellular proteins by enveloped viruses. J Virol 2005, 79:6577-6587.
2. Maxwell K.L., Frappier L. Viral proteomics. Microbiol Mol Biol Rev 2007, 71:398-411.
3. Antibodies: a laboratory manual 1988, Cold Spring Harbor, NY. D.L.E. Harlow (Ed.).
4. Mora J.R., Obenauer-Kutner L., Vimal Patel V. Application of the Gyrolab platform to ligand-binding assays: a user's perspective. Bioanalysis 2010, 2:1711-1715.
5. Dickerson M., Leong K., Sheldon K., Madison L. Developing custom Chinese hamster ovary-host cell protein assays using acoustic membrane microparticle technology. J Vis Exp 2011, (Feburary (48)):2493.
6. Nong R.Y., Gu J., Darmanis S., Kamali-Moghaddam M., Landegren U. DNA-assisted protein detection technologies. Expert Rev Proteomics 2012, 9:21-32.
7. Darmanis S., Nong R.Y., Vanelid J., Siegbahn A., Ericsson O., Fredriksson S., et al. ProteinSeq: high-performance proteomic analyses by proximity ligation and next generation sequencing. PLoS ONE 2011, 6:e25583.
8. Lovgren Bengtsson K., Morein B., Osterhaus A.D. ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines 2011, 10:401-403.
9. Reimer J.M., Karlsson K.H., Lovgren-Bengtsson K., Magnusson S.E., Fuentes A., Stertman L. Matrix-M adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS ONE 2012, 7:e41451.
10. Karlsson R. SPR for molecular interaction analysis: a review of emerging application areas. J Mol Recognit 2004, 17:151-161.
11. Grzeskowiak J.K., Tscheliessnig A., Toh P.C., Chusainow J., Lee Y.Y., Wong N., et al. Two-dimensional fluorescence difference gel electrophoresis for comparison of affinity and non-affinity based downstream processing of recombinant monoclonal antibody. J Chromatogr A 2009, 1216:4902-4912.
12. Grzeskowiak J.K., Tscheliessnig A., Toh P.C., Chusainow J., Lee Y.Y., Wong N., et al. 2-D DIGE to expedite downstream process development for human monoclonal antibody purification. Protein Expr Purif 2009, 66:58-65.
13. Shaw M.L., Stone K.L., Colangelo C.M., Gulcicek E.E., Palese P. Cellular proteins in influenza virus particles. PLoS Pathog 2008, 4:e1000085.